Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xeroderma
|
1 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2010 | 2010 | ||||
Gallbladder adenocarcinoma
|
2 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||
Carcinoma of urinary bladder, superficial
|
6 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2009 | 2009 | ||||
Carcinoma, Small Cell
|
7 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2005 | 2005 | ||||
progesterone receptor-negative breast cancer
|
11 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Carcinoma of urinary bladder, invasive
|
14 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||
Fibroid Tumor
|
14 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1 | 2019 | 2019 | |||||
progesterone receptor-positive breast cancer
|
17 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Xeroderma pigmentosum, group F
|
31 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2007 | 2007 | ||||
Xeroderma pigmentosum, group G
|
31 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2007 | 2007 | ||||
Xeroderma Pigmentosum
|
35 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||
Malignant neoplasm of skin
|
38 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||
Progressive cGVHD
|
40 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2010 | 2010 | ||||
Progressive Neoplastic Disease
|
40 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2010 | 2010 | ||||
Congenital chromosomal disease
|
47 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.020 | 1.000 | 2 | 2004 | 2012 | ||||
Stage 0 Gallbladder Cancer AJCC v8
|
56 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||
Stage IIA Gallbladder Cancer AJCC v8
|
56 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||
Stage IIB Gallbladder Cancer AJCC v8
|
56 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||
Stage III Gallbladder Cancer AJCC v8
|
56 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||
Stage IV Gallbladder Cancer AJCC v8
|
56 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||
Azoospermia
|
70 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2009 | 2009 | ||||
Gallbladder Carcinoma
|
75 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||
Differentiated Thyroid Gland Carcinoma
|
80 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||
Malignant neoplasm of gallbladder
|
81 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
82 | 0.570 | 0.480 | 3 | 14145949 | missense variant | G/T | snv | 0.63 | 0.65 | 0.100 | 0.875 | 16 | 2005 | 2019 |